Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2010

View Archived Issues

Phase I data show safety of proapoptotic receptor agonist antibody in advanced malignancies

Phase II investigation of inflammatory disease treatment CAL-263 planned for 2010

Prolastin-C to replace Prolastin in Canada

Sepracor plans to merge with Dainippon Sumitomo Pharma America

FDA approves Roche's rituximab plus FC chemotherapy in CLL

Depomed presents update on NDA for DM-1796 in postherpetic neuralgia

Octapharma initiates phase III trial of high-purity intravenous immunoglobulin

CHMP adopts negative opinion on ceftobiprole, Basilea regains rights

Merz to complete acquisition of BioForm Medical

Novel IGF-1R inhibitors disclosed by IRM

Array BioPharma discovers DP2 prostanoid receptor antagonists

AstraZeneca claims novel antipsychotic agents

Fluzone influenza virus vaccine safe and immunogenic in infants

Hydra Biosciences describes novel analgesic compounds

Genentech identifies novel Janus kinase inhibitors

Single-tablet formulation of elvitegravir/FTC/TDF/GS-9350 exhibits high virologic suppression in HIV

Sanofi Pasteur's A(H1N1) Humenza vaccine recommended by CHMP

Novavax presents clinical results for H1N1 vaccine at WHO conference

Final 96-week phase II data on elvucitabine vs. lamivudine in ART-naive HIV-1 patients disclosed

United Therapeutics withdraws European MAA for Tyvaso for PAH

Michael J. Fox Foundation awards funds for clinical trial of nicotine skin patch in PD

FDA approves Novartis' Menveo vaccine for meningococcal disease

FDA grants priority review to Novartis' Gilenia for the treatment of MS

Ablynx awarded grant to progress ALX- 0061 into clinical development

FDA sets PDUFA action date for Amgen's complete response submission for Prolia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...